Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04091932

Treatment of PD-1 Inhibitor in AIDS-associated PML — TPAP  

AIDS Clinical Trial

Official title:
The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study

Clinical Trial Summary

PD-1 inhibitor （Pembrolizumab, 2mg/kg weight, once per 4 weeks and 3 times of medication usage）treatment on AIDS patients with progressive multifocal leukoencephalopathy.

Clinical Trial Description

This is a one-center, single-arm and prospective study, planing recruiting 10 AIDS-associated PML patients. All patients will receive PD-1 inhibitor (Pembrolizumab) for 12 weeks, and the dose for each time is 2 mg per kg/weight, and the frequency is once per 4 weeks. The effect and safety of Pembrolizumab on AIDS-associated PML will be evaluated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04091932
Study type Interventional
Source First Affiliated Hospital of Zhejiang University
Contact Biao Zhu, PhD
Phone 13906535457
Email zhubiao1207@zju.edu.cn
Status Recruiting
Phase Phase 2
Start date August 20, 2019
Completion date December 2021
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Not yet recruiting NCT03661203 - Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02606344 - Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV N/A
Completed NCT01053598 - Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting N/A
Completed NCT01348308 - Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Phase 3
Completed NCT01237366 - Study Targeting Affect Regulation Phase 1/Phase 2
Withdrawn NCT00951795 - Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts N/A
Completed NCT00740389 - TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. Phase 1
Withdrawn NCT00347750 - Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations Phase 3
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Withdrawn NCT00340223 - HLA-B35 Alleles and AIDS N/A
Completed NCT00144352 - In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults Phase 4
Completed NCT01084395 - Reducing HIV Risk Among Mexican Youth N/A
Completed NCT00202241 - The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS N/A
Completed NCT00341172 - The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
Recruiting NCT06145841 - Metagenomic Next-Generation Sequencing Guides Anti-Infection Strategies
Completed NCT03633721 - Acute Effects of Cannabis on Cognition and Mobility in Older HIV-infected and HIV-Un-infected Women Phase 2
Completed NCT04567693 - Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV N/A
Completed NCT03023033 - Supporting Attendance for Facility Delivery and Infant Health N/A